30-Jul-2020 - Wacker Biotech B.V.

WACKER Invests in Amsterdam Biotech Site

The investment price is a mid-double-digit million-euro amount

WACKER, the Munich-based chemicals Group, is investing in its production facilities for biologics, LMPs (live microbial products) and vaccines at its Amsterdam site. Projects include the construction of a new fermentation line with a volume of 1,500 liters as well as the setting up of new cleanroom structures in the 270-liter fermentation line. The investment price is a mid-double-digit million-euro amount.

“By investing in new plants and production equipment, we are continuing to upgrade the Amsterdam site two years after WACKER took it over, and are making our company fit for the future,” explains Dr. Jörg Lindemann, managing director of the WACKER subsidiary Wacker Biotech B.V.

The construction of a new fermentation line with a volume of 1,500 liters is planned, which, after a transition period, will eventually supersede the existing 1,500-liter line. At the same time, new, improved cleanroom structures in the area of the 270-liter production line are to be created. The existing cleanrooms are to be gutted, completely renovated and successively re-equipped with state-of-the-art equipment. Among other improvements, new utility supplies are planned, such as water for injection. These measures will contribute to preparing the plant to produce new classes of actives, such as pDNA and mRNA-based vaccines. These nucleic acid-based actives classes are currently playing a role, for example, in the search for a vaccine against the new SARS Cov-2 corona virus.

“The strategic investment in our Amsterdam site is an important step in our continued growth in the fast-growing market for pharmaceuticals,” says Dr. Susanne Leonhartsberger, head of WACKER BIOSOLUTIONS, the company’s life-science division, justifying the investment decision. “The new structures, new equipment and new fermentation line will also enable us to reliably meet our customers’ demand in the next years. We will strengthen our position as one of the leading contract manufacturers in the field of microbial production of biologics,” adds Dr. Guido Seidel, head of the Biopharmaceuticals business line and managing director of Wacker Biotech GmbH.

Facts, background information, dossiers
  • WACKER
  • investments
  • mRNA vaccines
More about Wacker
  • News

    CureVac and WACKER Sign Manufacturing Contract for CureVac’s COVID-19 Vaccine Candidate

    CureVac N.V. and Wacker Chemie AG announced that they had signed a contract for the manufacturing of CureVac’s COVID-19 vaccine candidate CVnCoV. Under the terms of the initial agreement, WACKER will ramp up GMP (Good Manufacturing Practice) production of the mRNA drug substance for CVnCoV ... more

    SynCo Bio Partners B.V. is Now Wacker Biotech B.V.

    As of November 1, 2018, the pharmaceutical protein production facility in the Netherlands acquired by WACKER with its takeover of SynCo Bio Partners Luxembourg S.à r.l., will be renamed Wacker Biotech B.V. The site in Amsterdam for the manufacture of biopharmaceuticals, live microbial produ ... more

    WACKER Invests in Jena Biotech Site

    In Jena, the Munich-based chemical group WACKER has enhanced its production facilities for biopharmaceuticals – also known as biologics – with new equipment. Furthermore, an inspection by the Brazilian health authority ANVISA assessing the site’s quality standards was a major success. “In ... more

  • Companies

    Wacker Biotech GmbH

    more

    Wacker Biotech B.V.

    SynCo Bio Partners is a GMP-licensed bulk drug substance and final product CMO with clinical and commercial production experience with mammalian and microbial systems. This experience has been acquired by developing new production processes for a number of international clients and producin ... more